The Europe Iliac Stent Market would witness market growth of 5.5% CAGR during the forecast period (2023-2030).
The Germany market dominated the Europe Iliac Stent Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $87.7 million by 2030. The UK market is exhibiting a CAGR of 4.5% during (2023 - 2030). Additionally, The France market would experience a CAGR of 6.4% during (2023 - 2030).
Regulatory approvals, labelling indications, and post-market surveillance requirements imposed by regulatory agencies influence the adoption of iliac stent procedures and market access for stent manufacturers. Conformity to regulatory standards, adherence to good manufacturing practices (GMP), and compliance with safety and efficacy requirements are essential for obtaining marketing authorization and ensuring product quality and patient safety.
Regulatory bodies are vital in assessing the efficacy and safety of these using premarket review procedures, post-market surveillance initiatives, and continuous monitoring of unfavourable occurrences, hence influencing market dynamics and adoption patterns. Moreover, economic factors, including reimbursement policies, healthcare financing mechanisms, and cost-effectiveness considerations, impact the adoption of procedures and reimbursement decisions by payers and healthcare providers.
The UK has a considerable burden of PAD, with a significant proportion of the population affected by arterial occlusive disease. PAD often leads to symptomatic iliac artery stenosis or occlusions, necessitating vascular interventions such as its placement. According to the National Library of Medicine, about 15% to 20% of the UK population aged 55 to 75 years have evidence of lower extremity PAD on objective testing. Hence, the region’s high healthcare expenditure and prevalence of PAD drive the market’s growth.
Based on Artery Lesions, the market is segmented into Common Iliac Artery Lesions, Severe Calcified Lesions, and Complete Obstructive Lesions. Based on End-use, the market is segmented into Hospitals, Outpatient Facilities, and Others. Based on Type, the market is segmented into Self-expandable Stents, Balloon-expandable Stents, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The Germany market dominated the Europe Iliac Stent Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $87.7 million by 2030. The UK market is exhibiting a CAGR of 4.5% during (2023 - 2030). Additionally, The France market would experience a CAGR of 6.4% during (2023 - 2030).
Regulatory approvals, labelling indications, and post-market surveillance requirements imposed by regulatory agencies influence the adoption of iliac stent procedures and market access for stent manufacturers. Conformity to regulatory standards, adherence to good manufacturing practices (GMP), and compliance with safety and efficacy requirements are essential for obtaining marketing authorization and ensuring product quality and patient safety.
Regulatory bodies are vital in assessing the efficacy and safety of these using premarket review procedures, post-market surveillance initiatives, and continuous monitoring of unfavourable occurrences, hence influencing market dynamics and adoption patterns. Moreover, economic factors, including reimbursement policies, healthcare financing mechanisms, and cost-effectiveness considerations, impact the adoption of procedures and reimbursement decisions by payers and healthcare providers.
The UK has a considerable burden of PAD, with a significant proportion of the population affected by arterial occlusive disease. PAD often leads to symptomatic iliac artery stenosis or occlusions, necessitating vascular interventions such as its placement. According to the National Library of Medicine, about 15% to 20% of the UK population aged 55 to 75 years have evidence of lower extremity PAD on objective testing. Hence, the region’s high healthcare expenditure and prevalence of PAD drive the market’s growth.
Based on Artery Lesions, the market is segmented into Common Iliac Artery Lesions, Severe Calcified Lesions, and Complete Obstructive Lesions. Based on End-use, the market is segmented into Hospitals, Outpatient Facilities, and Others. Based on Type, the market is segmented into Self-expandable Stents, Balloon-expandable Stents, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
List of Key Companies Profiled
- Becton, Dickinson and Company
- Abbott Laboratories
- Boston Scientific Corporation
- W.L. Gore & Associates, Inc.
- Medtronic PLC
- Cook Medical, Inc.(Cook Group)
- Terumo Corporation
- iVascular S.L.U.
- Getinge AB
- Biotronik SE & Co. KG
Market Report Segmentation
By Artery Lesions- Common Iliac Artery Lesions
- Severe Calcified Lesions
- Complete Obstructive Lesions
- Hospitals
- Outpatient Facilities
- Others
- Self-expandable Stents
- Balloon-expandable Stents
- Others
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Europe Iliac Stent Market by Artery Lesions
Chapter 5. Europe Iliac Stent Market by End-use
Chapter 6. Europe Iliac Stent Market by Type
Chapter 7. Europe Iliac Stent Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Becton, Dickinson and Company
- Abbott Laboratories
- Boston Scientific Corporation
- W. L. Gore & Associates, Inc.
- Medtronic PLC
- Cook Medical, Inc.(Cook Group)
- Terumo Corporation
- iVascular S.L.U.
- Getinge AB
- Biotronik SE & Co. KG
Methodology
LOADING...
